{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:41:02Z","timestamp":1787164862727,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.dld.2021.10.011","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T23:30:02Z","timestamp":1636932602000},"page":"1094-1100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China"],"prefix":"10.1016","volume":"54","author":[{"given":"Qingling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Kui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4626-9828","authenticated-orcid":false,"given":"Qinglong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2021.10.011_bib0001","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems","volume":"22","author":"Goel","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2021.10.011_bib0002","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.cgh.2017.10.018","article-title":"Factors associated with prevalence and treatment of primary biliary cholangitis in united states health systems","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.10.011_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1385\/CRIAI:28:2:083","article-title":"Mitochondrial antigens as targets of cellular and humoral auto-immunity in primary biliary cirrhosis","volume":"28","author":"Ichiki","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.dld.2021.10.011_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-2007-1007185","article-title":"Nuclear envelope protein autoantibodies in primary biliary cirrhosis","volume":"17","author":"Courvalin","year":"1997","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2021.10.011_bib0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2005-916321","article-title":"Antinuclear antibodies in primary biliary cirrhosis","volume":"25","author":"Invernizzi","year":"2005","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2021.10.011_bib0006","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.10.011_bib0007","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis","volume":"42","author":"Nakamura","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.10.011_bib0008","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/s-0034-1383732","article-title":"Clinical significance of autoantibodies in primary biliary cirrhosis","volume":"34","author":"Nakamura","year":"2014","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.dld.2021.10.011_bib0009","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0896-8411(03)00033-7","article-title":"Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study","volume":"20","author":"Miyachi","year":"2003","journal-title":"J Autoimmun"},{"key":"10.1016\/j.dld.2021.10.011_bib0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","article-title":"Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?","volume":"2","author":"Yang","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.10.011_bib0011","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","article-title":"Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis","volume":"13","author":"Itoh","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.10.011_bib0012","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.10.011_bib0013","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.clinre.2020.03.026","article-title":"Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators","volume":"44","author":"Qian","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dld.2021.10.011_bib0014","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.10.011_bib0016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.10.011_bib0017","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hepr.12423","article-title":"Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2021.10.011_bib0018","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the american association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0019","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.10.011_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.dld.2021.10.011_bib0021","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.10.011_bib0022","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2017.06.020","article-title":"Primary biliary cholangitis: old and novel therapy","volume":"47","author":"Floreani","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.dld.2021.10.011_bib0024","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.10.011_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cld.2007.11.013","article-title":"Medical treatment of cholestatic liver disease","volume":"12","author":"Paumgartner","year":"2008","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2021.10.011_bib0026","first-page":"D9145","article-title":"Bezafibrate for primary biliary cirrhosis","volume":"1","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2021.10.011_bib0027","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0028","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.10.011_bib0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0032","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2011.00782.x","article-title":"Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis","volume":"41","author":"Azemoto","year":"2011","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2021.10.011_bib0033","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.10.011_bib0034","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0035","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0036","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.23637","article-title":"American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis","volume":"52","author":"Silveira","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.10.011_bib0037","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/bega.2000.0106","article-title":"The pathology of primary biliary cirrhosis and autoimmune cholangitis","volume":"14","author":"Ludwig","year":"2000","journal-title":"Baillieres Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2021.10.011_bib0038","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A"},{"key":"10.1016\/j.dld.2021.10.011_bib0039","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.14309\/ajg.0000000000001285","article-title":"A comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis","volume":"116","author":"Goet","year":"2021","journal-title":"AM J Gastroenterol"},{"key":"10.1016\/j.dld.2021.10.011_bib0040","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 3","key":"10.1016\/j.dld.2021.10.011_bib0041","first-page":"S412","article-title":"Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis","volume":"37","author":"Nakamura","year":"2007","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2021.10.011_bib0042","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/jgh.14521","article-title":"Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: a single center follow-up study from China","volume":"34","author":"Chen","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.10.011_bib0043","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1478-3231.2008.01715.x","article-title":"Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years","volume":"28","author":"Su","year":"2008","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.10.011_bib0044","first-page":"2075","article-title":"Erythrocyte count is associated with prognosis in Chinese patients with primary biliary cholangitis","volume":"19","author":"Chang","year":"2020","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.dld.2021.10.011_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31776","article-title":"Male sex is associated with higher rates of liver-related mortality in primary biliary cholangitis and cirrhosis","author":"John","year":"2021","journal-title":"Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821008161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821008161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:20:14Z","timestamp":1761625214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821008161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1590865821008161"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.10.011","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}